Collagenase: Preclinical Evaluation and Clinical Trials in the USA and Australia

  • Marie A. BadalamenteEmail author
  • Lawrence C. Hurst


Prior to US Food and Drug Administration approval of injectable collagenase, the standard of care was surgical fasciectomy, which in many cases can result in suboptimal treatment outcomes and a high recurrence rate. Injectable collagenase Clostridium histolyticum represents a novel, nonsurgical approach to the treatment of Dupuytren contracture. Early, proof-of-principle, basic science studies, using a rat tail tendon model and surgically removed Dupuytren cords, yielded favorable results. Clinical studies in humans were then conducted, where the primary end point was reduction in contracture to within 0–5° of normal extension (0°) after the last injection. Phase 2 studies which confirmed the optimal dose of collagenase as 10,000 units (0.58 mg) showed injectable collagenase reduced contractures in metacarpophalangeal (MP) and proximal interphalangeal (PIP) joints to within 0–5° of normal after the last injection in a substantial number of joints and was well tolerated. Clinical results from phase 3 studies confirmed the efficacy and safety of injectable collagenase as a viable nonsurgical intervention for the treatment of patients with Dupuytren contracture, translating the observations made in the laboratory into the clinical setting.


  1. 1.
    Badalamente MA, Hurst LC. Enzyme injection as a non-operative treatment for Dupuytren’s disease. Drug Deliv. 1996;3:35–40.CrossRefGoogle Scholar
  2. 2.
    Starkweather KD, Lattuga S, Hurst LC, Badalamente MA, Guilak F, Sampson S, Dowd A, Wisch D. Collagenase in the treatment of Dupuytren’s DISEASE: an in vitro study. J Hand Surg. 1996;21:490–5.CrossRefGoogle Scholar
  3. 3.
    Badalamente MA, Hurst LC. Enzyme injection as a non-operative treatment of Dupuytren’s disease. J Hand Surg. 2000;25(4):629–36.CrossRefGoogle Scholar
  4. 4.
    Badalamente MA, Hurst LC, Hentz VR. Collagen as a clinical target: non-operative treatment of Dupuytren’s disease. J Hand Surg. 2002;27(5):788–98.CrossRefGoogle Scholar
  5. 5.
    Badalamente MA, Hurst LC. Efficacy and safety of injectable mixed collagenase subtypes in the treatment of Dupuytren’s contracture. J Hand Surg. 2007;32(6):767–74.CrossRefGoogle Scholar
  6. 6.
    Hurst LC, Badalamente MA, Hentz VR, Hotchkiss RN, Kaplan TD, Meals RA, Smith TN, Rodzvilla J. Injectable collagenase clostridium histolyticum for Dupuytren’s contracture. N Engl J Med. 2009;361:968–79.CrossRefPubMedGoogle Scholar
  7. 7.
    Gilpin D, Coleman S, Hall S, Houston A, Karrasch J, Jones N. Injectable collagenase clostridium histolyticum: a new nonsurgical treatment for Dupuytren’s disease. J Hand Surg. 2010;35:2027–38.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of OrthopaedicsStony Brook University Medical CenterStony BrookUSA

Personalised recommendations